GAINESVILLE, Fla. — Neuropacs™ Corp., a leader in AI-powered neurodiagnostics, today announced the appointment of Dr. Jesse DeSimone as Director of Clinical and Business Development. In this role, Dr. DeSimone will drive clinical evidence generation, commercial partnerships, and go-to-market strategy for Neuropacs’ suite of AI-powered imaging tools, advancing the company’s mission to improve diagnosis and monitoring of Parkinson’s disease, Alzheimer’s disease, and related neurodegenerative conditions.
A neuroscientist and clinical innovator with experience spanning academia, industry, and strategy consulting, Dr. DeSimone brings a unique combination of scientific rigor, regulatory expertise, and commercial acumen to his new role. He joins the company from the University of Florida, where his research program focused on developing next-generation imaging biomarkers and AI algorithms to improve early detection, differential diagnosis, and precision monitoring of movement and dementia disorders. He previously served as Scientific Consultant for the company, where he led the regulatory strategy and De Novo FDA submission for Neuropacs AIDP — the first FDA-authorized diagnostic aid for Parkinsonian syndromes.
“Jesse’s combination of scientific depth, regulatory discipline, and commercial instinct is exactly what Neuropacs needs as we scale our clinical impact across Parkinson’s, Alzheimer’s, and related neurodegenerative diseases. His leadership in evidence generation and strategic partnerships will accelerate our ability to deliver AIpowered diagnostics that raise the standard of care for patients and strengthen the workflows clinicians rely on every day,” said Dr. Martin Handfield, President & CEO of Neuropacs. “Neuropacs is building an AI software suite with transformative potential to improve neurology workflows, advance patient care, and optimize drug development, and I am excited to help scale that mission through clinical evidence generation, strategic partnerships, and commercial execution.” added Dr. DeSimone.
About Neuropacs™ Corp.
Neuropacs™ Corp. is an AI-enabled imaging company focused on developing software tools to support the evaluation of neurodegenerative diseases. Automated Imaging Diagnostics LLC, is a wholly owned subsidiary of Neuropacs Corp. Its platform leverages advanced imaging analytics to provide insights for clinical and research applications. https://sharp-northcutt.74-208-86-71.plesk.page/
About neuropacs™
neuropacs™ is a prescription device that analyzes patient-specific data to aid in the diagnosis of Parkinsonian syndromes. The test requires a single, non-invasive, and radiotracer-free diffusion MRI scan, which can be acquired using standard diffusion MRI sequences available on 3 Tesla clinical MRI systems from Siemens, GE Healthcare, and Philips. The brain scan is analyzed using a rigorously validated free-water imaging model and machine learning algorithm. The device provides a classification report based on degenerative brain patterns of multiple system atrophy Parkinsonian variant (MSAp) and progressive supranuclear palsy (PSP) to help neuroradiologists and/or neurologists in differentiating these diseases from Parkinson’s disease (PD). Important Safety Information: The neuropacs™ system is intended to provide supplemental information and is not a standalone diagnostic device. Results should be interpreted in conjunction with clinical evaluation and other diagnostic testing. This device does not rule out other potential causes of Parkinsonism symptoms or signs and is intended to be used after all other potential causes of Parkinsonism symptoms (such as dementia with Lewy bodies, vascular Parkinsonism, drug-induced Parkinsonism, and corticobasal degeneration/syndrome) have been ruled out by trained clinicians on the basis of clinical, neurological, and other laboratory tests. Patient management decisions should not be based solely on neuropacs™ output.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.
Follow the Conversation
Stay up to date with the latest company announcements and industry insights by following @neuropacs on LinkedIn, X, and Instagram.
Media Contact: Martin Handfield, President & CEO, martin@neuropacs.com